Compare Liberty Global Ltd Class C (LBTYK) vs Eli Lilly And Co (LLY) Price & Performance

LBTYK trades at $10.24, down 2.38% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion in 2025, though operating cash flow remains positive at $1.21 billion. Recent news highlights the completion of the VodafoneZiggo buyout and preparations for a 2027 Ziggo Group listing, a key strategic move.

Despite deep losses, the stock appears undervalued on price-to-sales (0.7) and price-to-book (0.37) metrics. Analyst sentiment is strongly bullish (69% buy ratings), seeing upside from asset monetization and the Ziggo spin-off. Key risks include persistent negative margins and execution of the separation plan.

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.